Lung Cancer Trial, Recruiting NCT04977791 Sponsor: Shanghai Chest Hospital Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT04977791
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give informed consent and agree to follow the study requirements
  • People diagnosed with advanced non-small cell lung cancer
  • People currently receiving immune checkpoint inhibitor treatment, specifically a type of drug known as an anti-PD-1/PD-L1 monoclonal antibody
  • People who are able to provide tumor tissue samples (either fresh samples taken before and after treatment, or stored tissue from within the past year) along with a blood sample
  • People whose general physical fitness is rated at ECOG level 0 or 1, meaning they are able to carry out normal daily activities with little or no restriction (confirm with trial site)
  • People who have at least one tumour that can be measured using standard imaging guidelines
  • People with a life expectancy of at least 12 weeks
  • People whose blood counts and organ function (including liver and blood clotting measures) meet the required levels within 7 days before treatment begins (confirm with trial site for specific values)

Who may not be able to join:

  • People who have another active cancer, except for certain early-stage or treated skin or cervical cancers that have not returned within the past 5 years
  • People who have previously received approved systemic anti-tumour immunotherapy before entering the study
  • People with a history of interstitial lung disease, non-infectious pneumonia, or uncontrolled conditions such as diabetes, high blood pressure, pulmonary fibrosis, or acute lung disease
  • People with severe ongoing or active infections requiring antibiotics, antifungal, or antiviral treatment, including tuberculosis
  • People with a known HIV infection, or who have previously had a stem cell transplant or organ transplant
  • People whom the study investigator believes may not be able to reliably follow the study requirements throughout the trial period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai Chest Hospital
Registry
ClinicalTrials.gov
Start date
21 July 2016
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate (ORR); Progression-free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov